WealthBridge Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

WealthBridge Capital Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-79	Closed	-$3K	–	939
2019 Q1	$3K	Buy	+79	New	+$3.48K	﹤0.01%	781

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

WealthBridge Capital Management's AERI Position: Q2 2019 in Review

WealthBridge Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q2 2019, closing a stake of 79 shares — an estimated $3K sold.

WealthBridge Capital Management first reported a position in AERI in Q1 2019 and held it in 1 quarter. The position peaked at $3K in Q1 2019. 167 funds tracked by Wall St. Rank hold AERI as of Q2 2019.

WealthBridge Capital Management reported no remaining Aerie Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
WealthBridge Capital Management sold 79 Aerie Pharmaceuticals shares in Q2 2019, an estimated $3K.
WealthBridge Capital Management first reported a position in Aerie Pharmaceuticals in Q1 2019 and held it in 1 quarter.
WealthBridge Capital Management's Aerie Pharmaceuticals position peaked at $3K in Q1 2019.
167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2019.

Based on WealthBridge Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.